Xenazine (tetrabenazine) is a medicine that Lundbeck Pharmaceuticals developed to treat one of the symptoms of Huntington’s disease known as chorea. Chorea refers to the involuntary and uncontrollable dance-like movements that affect people with Huntington’s disease. It has been approved by the U.S. Food and…
People with Huntington’s disease are more likely to take Austedo (deutetrabenazine) as directed, compared with the similar medication Xenazine (tetrabenazine), according to a new study. The study also found lower discontinuation rates with Austedo, which may suggest that, between these two treatments for chorea, Austedo tends to…
Huntington’s patients who are taking Xenazine for the twitching condition known as chorea can switch without concern to the newly approved Austedo, according to Austedo’s maker, Teva Pharmaceutical Industries. A Phase 3 clinical trial showed that the switch was safe and that Austedo (deutetrabenazine) did a better job of controlling chorea than…
While the vast majority of Huntington’s disease patients in North America have the uncontrolled and jerky movements known as chorea at clinically relevant levels, about a third of these people are getting medications specifically for this motor symptom. Among treated patients, about half are prescribed VMAT2 inhibitors, the…
SRX246 is an oral therapy that was being developed by Azevan Pharmaceuticals to help ease irritability and aggressive behavior related to Huntington’s. Tested in a Phase 2 trial, the therapy’s development program appears to have been discontinued.
Seroquel (quetiapine) is an antipsychotic medication marketed by AstraZeneca for the treatment of schizophrenia and bipolar disorder. It is also used along with antidepressants to treat depression. In Huntington’s disease, Seroquel has been shown to improve behavioral symptoms and may decrease chorea,…
Abilify (aripiprazole) is an antipsychotic medication manufactured by Otsuka and Bristol-Myers Squibb. It is approved by the U.S. Food and Drug Administration to treat psychiatric disorders such as schizophrenia. It may also be prescribed off-label to treat some symptoms of Huntington’s disease, such…
SOM3355 is an experimental treatment being developed by SOM Biotech to treat movement disorders in Huntington’s disease. SOM Biotech is currently seeking orphan drug status for SOM3355 from the U.S. Food and Drug Administration (FDA). Huntington’s disease is caused by a mutation in the huntingtin (HTT) gene.
The outlook for the Huntington’s disease community has never been brighter, with better care options and promising new research already in progress, the president and CEO of the Huntington’s Disease Society of America said at the organization’s 39th annual convention, taking place in Spokane, Washington. “There has never…
Last updated Sept. 12, 2023, by Marta Figueiredo, PhD  Fact-checked by Inês Martins, PhD What is Austedo for Huntington’s disease? Austedo (deutetrabenazine) is an approved oral therapy used to treat adults with chorea, or involuntary and uncontrolled movements, associated with Huntington’s disease. It is also…
Get regular updates to your inbox.
